Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosamprenavir - Vertex Pharmaceuticals/GlaxoSmithKline

Drug Profile

Fosamprenavir - Vertex Pharmaceuticals/GlaxoSmithKline

Alternative Names: 433908; 908; GW-433908; Lexiva; Telzir; VX-175

Latest Information Update: 11 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer GlaxoSmithKline; Vertex Pharmaceuticals
  • Class Antiretrovirals; Carbamates; Phosphoric acid esters; Small molecules; Sulfonamides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 11 Jul 2019 Discontinued - Phase-II for HIV infections (In adolescents, In children) in Romania, Spain, South Africa, Russia, Canada, Belgium, USA (PO) (NDR batch #16)
  • 11 Jul 2019 Discontinued - Phase-II for HIV infections (In infants) in South Africa, Russia, Portugal, Latin America, USA (PO) (NDR batch #16)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top